INTERNATIONAL SEARCH REPORT

al Application No PCT/EP 03/03958

a. classification of subject matter IPC 7 C12Q1/68 G01N33/53 A01K67/027 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols) $IPC\ 7\ C12Q$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, Sequence Search, EMBL

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GENESEQ [Online] EBI; 2 July 1999 (1999-07-02), "GASTRIC CANCER ASSOCIATED GENE" XP002257871 Database accession no. AAX39745	8,11,18, 19
A	abstract -& WO 99/04265 A (SAHIN UGUR ;TURECI OZLEM (DE); PFREUNDSCHUH MICHAEL (DE); GOUT IVA) 28 January 1999 (1999-01-28) See page 19, page 27 line 27-line 29.	1-7, 13-15,20

Further documents are listed in the continuation of box C. * Special categories of cited documents:	Patent family members are listed in annex. The later document published after the international filing date or priority date and not in conflict with the application but		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed	cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family		
Date of the actual completion of the international search 28 October 2003	Date of mailing of the international search report 1 4 01 2004		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Hagenmaier, S		



International Application No
PCT/EP 03/03958


		PUT/EP 03/03958	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	FRITZLER ET AL: "MOLECULAR CHARACTERIZATION OF GOLGIN-245, A NOVEL GOLGI COMPLEX PROTEIN CONTAINING A GRANIN SIGNATURE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 52, 29 December 1995 (1995-12-29), pages	8,18,19	
A	31262-31268, XP002136607 ISSN: 0021-9258 the whole document	1-7, 11-15,20	
X	ERLICH ET AL: "MOLECULAR CHARACTERIZATION OF TRANS-GOLGI p230" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 14, 5 April 1996 (1996-04-05), pages 8328-8337, XP002136608	8,18,19	
A	ISSN: 0021-9258 the whole document	1-7, 11-15,20	
X	DATABASE SWALL [Online] EBI; 16 October 2001 (2001-10-16), "GOLGI-AUTOANTIGEN" XP002256502 Database accession no. Q13439	8,18,19	
A	abstract	1-7, 11-15,20	
A	WO 00/65340 A (MYRIAD GENETICS INC) 2 November 2000 (2000-11-02) the whole document	1-8, 11-15,20	
A	EP 1 188 839 A (EVOTEC NEUROSCIENCES GMBH) 20 March 2002 (2002-03-20) the whole document	1-8, 11-15,20	
A	WO 02/16636 A (EVOTEC NEUROSCIENCES GMBH; HIPFEL RAINER (DE); KRAPPA RALF (DE); P) 28 February 2002 (2002-02-28) the whole document	1-8, 11-15,20	
A	LORING J F ET AL: "A gene expression profile of Alzheimer's disease." DNA AND CELL BIOLOGY. UNITED STATES NOV 2001, vol. 20, no. 11, November 2001 (2001-11), pages 683-695, XP002233087 ISSN: 1044-5498 the whole document	1-8, 11-15,20	
	-/		



Intermedial Application No PCT/EP 03/03958

TO SERVICE A PRODUMENTS CONSIDERED TO BE BELLEVANT		FC1/EF 03/03/30		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No				
Category °	Citation of document, with improation, where appropriate, of the relevant passages	Heleval to daming.		
A	PASINETTI G M: "Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia." JOURNAL OF NEUROSCIENCE RESEARCH. UNITED	1-8, 11-15,20		
-	STATES 15 SEP 2001, vol. 65, no. 6, 15 September 2001 (2001-09-15), pages			
· ·	471-476, XP002233371 ISSN: 0360-4012 the whole document			
A	"Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group." NEUROBIOLOGY OF AGING. UNITED STATES 1998 MAR-APR, vol. 19, no. 2, March 1998 (1998-03), pages 109-116, XP002233088 ISSN: 0197-4580 the whole document	1-8, 11-15,20		
Т	WO 02/38803 A (DEUTSCHES KREBSFORSCH; USENER DIRK (DE); EICHMUELLER STEFAN (DE);) 16 May 2002 (2002-05-16) the whole document	1-8, 11-15,20		





Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 9 because they relate to subject matter not required to be searched by this Authority, namely: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. X Claims Nos.: 10 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box fl Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. X As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-15, 18-20 (completely)
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15,18-20 (completely)

Methods of diagnosing, prognosticating, monitoring the progression or evaluating a treatment of a neurodegenerative disease comprising determining the level and/or activity of a transcription/translation product of a gene coding for golgin 245 in a sample as well as a kit for diagnosing or prognosticating a neurodegenerative disease comprising at least one reagent that selectively detects a transcription/translation product of a gene coding for golgin 245, a protein molecule being a translation product of the gene coding for golgin-245 for use as a diagnostic /screening target for a neurodegenerative disease, use of an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of a gene coding for golgin-245 for detecting a neurodegenerative disease; a recombinant, non-human animal comprising a non-native gene sequence coding for golgin-245; assays or method for screening for a modulator of neurodgenerative diseases of one or more substances selected from the group consisting of the golgin 245 gene, the transcription or translation product of said gene.

2. claims: 16,17 (completely)

An assay for testing a compound, preferably for screening a plurality of compounds for inhibition of binding between a ligand and golgin-245 protein and an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to golgin-245 protein.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 9

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 10

Present claim 10 relates to a product defined by reference to a desirable characteristic or property, namely being a modulator of an activity or a level of at least one substance selected from the group listed in claim 10 under (i)-(iv). The claim covers all products having this characteristic or property, whereas the application does not provide any support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such products. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. Consequently, no search has been carried out for claim 10.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Internation No PCT/EP 03/03958

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9904265 A	28-01-1999	US US US AU EP JP WO US	6218521 B1 6043084 A 6493373 B1 8571598 A 0996857 A2 2001516009 T 9904265 A2 2002037541 A1 6517837 B1	17-04-2001 28-03-2000 11-06-2002 10-02-1999 03-05-2000 25-09-2001 28-01-1999 28-03-2002 11-02-2003
WO 0065340 A	02-11-2000	AU CA EP JP WO	4475400 A 2371006 A1 1181549 A1 2002542774 T 0065340 A1	10-11-2000 02-11-2000 27-02-2002 17-12-2002 02-11-2000
EP 1188839 A	20-03-2002	EP	1188839 A1	20-03-2002
WO 0216636 A	28-02-2002	AU WO EP	8983401 A 0216636 A2 1377678 A2	04-03-2002 28-02-2002 07-01-2004
WO 0238803 A	16-05-2002	DE AU WO EP	10055285 A1 1897702 A 0238803 A2 1349871 A2	06-06-2002 21-05-2002 16-05-2002 08-10-2003